TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, et al. Blood 2020;136:2812-2823.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood 2020;136:2812-2823.
PMID: 32730593